151751-Najiba-Chargi

188 CHAPTER 10 Table 3. Cisplatin dose-limiting toxicities according to SMM status Total n=343 n (%) Without low SMM n=144 n (%) Low SMM n=199 n (%) p-value DLT No Yes 189 154 92 (48.7) 52 (33.8) 97 (51.3) 102 (66.2) <0.01 < 3 cycles No Yes 198 145 94 (47.5) 50 (34.5) 50 (34.5) 95 (65.5) 0.02 Delay ≥ 4 days No Yes 337 6 142 (42.1) 2 (33.3) 195 (57.9) 4 (66.7) 0.71 De-escalation ≥ 50% No Yes 340 3 144 (42.4) 0 196 (57.6) 3 (100) 0.27 Reason DLT Ototoxicity No Yes 279 64 123 (44.1) 21 (32.8) 156 (55.9) 43 (67.2) 0.12 Neurotoxicity No Yes 342 1 144 (42.1) 0 198 (57.9) 1 (100) 1.00 Hematopoietic toxicity No Yes 331 12 139 (42) 5 (41.7) 192 (58) 7 (58.3) 1.00 Nephrotoxicity No Yes 302 41 170 (56.3) 29 (70.7) 132 (43.7) 12 (29.3) 0.09 Vascular toxicity No Yes 337 6 140 (41.5) 4 (66.7) 197 (58.5) 2 (33.3) 0.41 Malaise No Yes 314 29 134 (42.7) 10 (34.5) 180 (57.3) 19 (65.5) 0.44 Patients with low SMMwere more likely to experience cisplatin DLT (n=102, 66.2%) compared to patients without low SMM (n=52, 33.8%) (p<0.01). When comparing the causes of cisplatin DLT with SMM status, patients with low SMM were in particular more likely to not complete all cycles (n=3) of cisplatin (n=95, 65.5%) compared to patients without low SMM (n=50, 34.5%) (p=0.02). Patients who experienced cisplatin DLT were shown to have received significantly higher cisplatin doses per kg of LBM.